Site Members can sign up for company wide alerts
Investigation Overview
December 26, 2014 (Update) - On December 17, 2014, POZEN Inc announced that its investigational drug candidates YOSPRALA 81/40 and 325/40 received a second complete response letter from the FDA. In this complete response letter, the FDA used identical wording to that of the first complete response letter. Shares of POZEN Inc. (NASDAQ:POZN) declined to as low as $7.62 per share on Dec...
You must register (for free) or login to view the entire investigation.